The age-related macular degeneration market size is estimated to be USD 9,875.2 million in 2022 and is expected to witness a CAGR of 7.12% during the forecast period 2023-2033. Increasing R&D investments, expanding geriatric population, surging number of people with retinal disorders, product launch and approval, and medicines for the treatment of dry AMD are factors contributing to the market growth. However, rising off-label use of pharmaceuticals and lack of knowledge about the disease is expected to hinder the growth.

Surging number of people with retinal disorders is expected to stimulate the market growth. According to statistics, the market expansion is significantly associated with the rising number of people suffering from retinal problems. Thus, the growing prevalence of these conditions is fuelling demand for macular degeneration treatments, which is further boosting market growth.

Product approval and launch is predicted to propel the market growth. For the treatment of wet AMD, myopic choroidal neovascularization, and retinal vein occlusion, Biogen Inc. and Samsung Bioepis Co., Ltd. acquired U.S. FDA approval for their biosimilar version of Lucentis in September 2021 under the brand name BYOOVIZ. However, in June 2022, the product was launched in U.S. due to required additional protection certificates. In August 2021, the product also obtained approval in EU nations, including the UK.

Segmentation

 By Product

The market is categorized into lucentis, beovu, eyelea, and others. In the global market, the eyelea segment accounted for the largest revenue share in 2022 owing to the increased market penetration and patent protection. Additionally, patients taking Beovu reported four times greater intraocular inflammation than those taking eylea, according to study studies. Lucentis is anticipated to hold the biggest market share over the future years due to introduction of a novel drug delivery method.

 By Disease Type

The market is bifurcated into wet AMD and dry AMD. In 2022, the wet AMD segment accounted for the highest revenue share due to growing geriatric population around the world as AMD is the most common cause of substantial loss of vision in people over 50. Dry AMD is predicted to experience the fastest growth throughout the forecast period owing to planned introduction of potential product candidates.

 By Route of Administration

The market is divided into intravitreal and intravenous. In the global market, the intravitreal segment accounted for the largest revenue share in 2022 owing to its more effective method of medication administration. Additionally, increasing adoption of intravitreal route of administration in major regions to expected to support the market growth. Moreover, intravitreal injections are used to provide the majority of anti-VEGF injections.

By Distribution Channel

The market is segmented into hospital pharmacy, online pharmacy, specialty pharmacy. In 2022, the hospital pharmacy segment accounted for the largest revenue share owing to increase in age-related macular degeneration (AMD) incidence and hospitalisation for treatment. Specialty pharmacy segment is anticipated to experience the quickest growth throughout the projection period due to simplicity of drug availability and reimbursement coverage provided by specialty pharmacies. simplicity of drug availability and reimbursement coverage provided by specialty pharmacies

Regional Markets

In 2022, North America region accounted for the highest revenue in the age-related macular degeneration market and is expected to maintain its dominance during the forecast period. This is attributed to the rising incidence of AMD. Around 15 million people in North America have AMD, according to the American Academy of Ophthalmology. In 2021, Europe had the second-largest market share. This is because macular degeneration is extremely common in Europe and is expected to increase by about 20% by the year 2050. Asia Pacific is anticipated to experience the quickest growth during the projection period due to large geriatric population and disease burden. The market growth can be influenced by the positive government actions to help the affordability of pricey anti-VEGF medications.

Competitor Insights

Some of the key players operating in the age-related macular degeneration market are Acucela Inc., ALLERGAN, Santen Pharmaceuticals Co., Bausch & Lomb Incorporated, Bayer AG, Novartis AG, F. Hoffmann La Roche, GlaxoSmithKline PLC, Ophthotech Corporation, Pfizer Inc, Alimera Sciences Inc., Rxi Pharmaceuticals Inc., Ocular Therapeutix Regeneron Pharmaceuticals, Mosaic Biosciences,  and Valeant Pharmaceuticals International, Inc. among others.

Companies are forming a variety of strategic agreements to expand in different areas. Research spending have escalated in an effort to create AMD treatments.

• A collaboration between Mosaic Biosciences and Ocular Therapeutix was established in 2021 with the goal of improving treatments for dry age-related macular degeneration.
• In 2021, Bioeq and Teva Pharmaceuticals formed a business alliance to develop medicines for ophthalmology.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, disease type, route of administration, and distribution channel from 2023 to 2033.

Report Scope:

Segmentation: Age-related Macular Degeneration Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Lucentis
• Beovu
• Eyelea
• Others

Disease Type (Revenue, USD Million), 2022 – 2033

• Wet AMD
• Dry AMD

Route of Administration (Revenue, USD Million), 2022 – 2033

• Intravitreal
• Intravenous

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Hospital Pharmacy
• Online Pharmacy
• Specialty Pharmacy

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA